Focus Stocks
Amgen Broke Support
Published on Thursday, 26 August 2010 05:44 Written by TradersHuddle Staff
New York, August 26th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) closed the trading session at $51.84 below calculated support at $53.04 breaking the stock technically, raising concerns by investors, as the move might trigger more selling.
Amgen Inc. (NASDAQ:AMGN) develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The company concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
Amgen's stock was trading in a well defined range with support at $53.04 and resistance at $56.14; given that this range was broken traders will be closely monitoring the stock?s price action for clues of direction.
From a technical perspective it can be expected that previous support becomes resistance, as the new range gets defined, however, given that Amgen's stock is still near the broken support, traders will be focusing on $53.04 to see if the stock can bounce back and return to its previous range.
Traders wanting to establish a short position in Amgen can do so if the stock breaks the intraday low, or if the stock bounces back and selling materializes again at previous support of $53.04. For traders wanting to establish a long position, wait for price action to take the stock back to calculated support, which will provide a best entry point to build the position.
Related Articles
- NASDAQ 100 Mid-day Update: Lower Top Performers: VRTX, FSLR, GILD
- Amgen near Resistance
- Is Amgen Breaking Out?
- Trading Idea - Is Amgen close to Resistance?
- Amgen Higher Ahead of Earnings
- Amgen near Key Resistance Area
- Up/Downgrades ( COP, FST, CMA, PNRA, ARW, AVT, ALTH, ACOR, AMGN, FST )
- Is Amgen Breaking Out?
- Amgen - Shares Seeking Direction
- Amgen - 52 Week High
Related Partner Headlines
- Deutsche Bank: Xgeva Not Proceeding Well for Amgen - Benzinga
- Amgen to Discuss Application for New Use of XGEVA at FDA Oncologic Drugs Advisory Committee Meeting - Benzinga
- Dendreon Rockets 17% After Critical Reveiw For Amgen's Cancer Drug - Benzinga
- Piper Jaffray Postive on Amgen After FDA Releases Briefing Documents on Xgeva - Benzinga
- FDA Skeptical of Amgen Drug Ahead of Panel - TheStreet.com
- Amgen Reaches New 52-Week High (AMGN) - TheStreet.com
- Stock Market Story: Jan. 27 - TheStreet.com
- Stocks to Watch: P&G, Ford, Starbucks - TheStreet.com
- Amgen Acquires Micromet for $1.16 Billion - TheStreet.com
- Limitations of Beta-Weighted Delta Hedging - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
-
Benzinga's Microcap Movers for Wednesday February 8, 2012 - Benzinga -
Five More Stocks ETFs Need More Of - Benzinga -
ETFs to Watch February 9, 2012 - Benzinga -
'Fast Money' Recap: Cisco's Back - TheStreet.com -
Benzinga's M&A Chatter for Wednesday February 8, 2012 - Benzinga -
Market Preview: Fearing the Inevitable Pullback - TheStreet.com -
Mike Khouw's OpenTable Inc Trade - Benzinga -
Fast Money Picks For February 9th - Benzinga
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,883.95 Trade time:4:02PM EST Value change:▲5.75 (0.04%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,349.96 Trade time:4:31PM EST Value change:▲2.91 (0.22%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,915.86 Trade time:5:16PM EST Value change:▲11.78 (0.41%)In The Wires
-
EpiCept to Raise $2 Million in Registered Direct Offering -
The Eco Picture Diary Global Contest Ceremony and Partnership Press Event held at the UNESCO Headquarters -
3D Systems Brings 3D Content-to-Print Products and Services to PD&M -
Evolution Petroleum Reports Fiscal 2012 Second Quarter Results -
Energizer Extends Exchange Offer for $600 Million of Its 4.700% Senior Notes Due 2021 -
ICOA Partners with iPhoneTrip to Offer Data Sim Cards -
Cielo: Record Net Income of R$505 Million in 4Q11 and R$1.8 Billion in 2011 -
Pilgrim's Pride Announces Extension of Its Rights Offering










